Recruiting Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB) NCT07185256 Conditions ARB, Autosomal-Dominant Bestrophinopathy, BVMD, +10 more Locations Children's Hospital Los Angeles — Los Angeles, California, United States Vitreo Retinal Associates — Gainesville, Florida, United States Cincinnati Eye Institute — Cincinnati, Ohio, United States Retina Foundation of the Southwest — Dallas, Texas, United States View Trial Details
Recruiting Study of BEST1 Vitelliform Macular Dystrophy NCT05809635 Conditions Best Vitelliform Macular Dystrophy, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, +8 more Locations Columbia University Irving Medical Center — New York, United States Institut de la Vision/Centre de maladies rares du Centre Hospitalier National Ophtalmologique des Quinze-Vingts — Paris, France Eberhard Karls University Tubingen — Tübingen, Germany View Trial Details
Completed Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases. NCT02162953 Conditions Adult Onset Vitelliform Macular Dystrophy, Autosomal Dominant Vitreoretinalchoroidopathy, Best Vitelliform Macular Dystrophy, +10 more Locations Mayo Clinic — Rochester, Minnesota, United States View Trial Details
